Please login to the form below

Not currently logged in

Flying the industry standard

How can communications agencies help in ensuring adherence to Good Publication Practice

A series of flagsThe introduction of Good Publication Practice (GPP) standards marked an important step towards the ethical and transparent development of publications from pharma- and biotech-sponsored medical research. How can adherence to these standards be ensured, and how can medical communications agencies help accomplish this?

The environment in which medical research sponsored by pharma and biotech is reported has evolved during the past decade. Industry has taken several initiatives to move towards greater awareness, full transparency and improved practices. GPP guidelines were first published in 2003. The GPP-2 guidelines, published in 2009, can be viewed as the most up-to-date industry standards. They describe the responsibilities of authors, collaborators and industry for developing publications in a responsible and ethical manner.

In addition, the American Medical Writers Association and the European Medical Writers Association have formulated guidance on the role of professional writers in developing publications. GPP standards have been formulated and endorsed by medical publication professionals from both pharma and biotech, medical communications agencies and publishers. As such, these standards represent self-regulation and are not monitored or enforced by regulatory authorities. The International Society for Medical Publication Professionals has implemented a certification programme. Through the Certified Medical Publication Professional credential, integrity is promoted by encouraging adherence to best-practice standards across the industry.

Auditing good practice
The development of GPP standards has been essential for ensuring responsible and ethical practice. However, the dissemination of guidelines and education on standards do not guarantee that companies and individuals actually adhere to best-practice standards. If industry wants to – or ends up needing to – demonstrate adherence, documented evidence is required. One approach is to create auditable processes to evaluate and document adherence to GPP. Quality assurance and auditing are well established on a global level in other fields, such as good clinical practice and market research.

Working to GPP standards
Medical communications agencies partnering with pharma and biotech, authors and publishers, can contribute to GPP adherence by creating robust processes to ensure that all steps in publication development are in line with GPP and evidence of this is properly documented. These steps facilitate the creation of effective auditable processes:

• Educate all staff to understand the intention of responsible publication practices
• Integrate GPP into the company's standard operating procedures so that it becomes an everyday practice
• Document GPP steps and procedures across all projects
• Audit publication development processes for internal tracking, improvement and external validation of adherence
• Innovate processes to facilitate effective adherence to GPP, while minimising bureaucratic paperwork
• Have an in-house champion to stay at the forefront of developments and to drive internal engagement.

An auditable trail of publication development will benefit all partners: the medical communications agency can track and improve its performance of GPP; authors are assured that they direct publications that express their views accurately; publishers are guaranteed that the medical research they publish has been reported in a transparent and ethical manner; and industry can use the auditable trail of documentation as a tool to demonstrate adherence with standards. By operating together with transparency towards high-quality and accurate reporting of medical research, we can have a positive impact on the evidence base that healthcare providers use to make decisions and, ultimately, on patient care.


Hester van LierThe AuthorExcerpta Medica
Hester van Lier,
PhD is programme director at Excerpta Medica
Email her at:







15th March 2011


COVID-19 Updates and Daily News

Featured jobs


Add my company

A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...